Phospho-CTNNB1 (Y654) Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Lead Time
Typically, we can ship products within 1-3 business days of receiving your order. Delivery times may vary depending on the purchasing method or location. Please contact your local distributor for specific delivery timeframes.
Synonyms
b-catenin antibody; Beta catenin antibody; Beta-catenin antibody; Cadherin associated protein antibody; Catenin (cadherin associated protein); beta 1; 88kDa antibody; Catenin beta 1 antibody; Catenin beta-1 antibody; CATNB antibody; CHBCAT antibody; CTNB1_HUMAN antibody; CTNNB antibody; CTNNB1 antibody; DKFZp686D02253 antibody; FLJ25606 antibody; FLJ37923 antibody; OTTHUMP00000162082 antibody; OTTHUMP00000165222 antibody; OTTHUMP00000165223 antibody; OTTHUMP00000209288 antibody; OTTHUMP00000209289 antibody
Target Names
Uniprot No.

Target Background

Function
Phospho-CTNNB1 (Y654) Antibody is a key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, it forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B, promoting phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC. This ultimately leads to the degradation of CTNNB1 by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family. This activation results in the expression of Wnt responsive genes. Phospho-CTNNB1 (Y654) Antibody plays a crucial role in regulating cell adhesion as a component of the E-cadherin:catenin adhesion complex. It also acts as a negative regulator of centrosome cohesion and participates in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Furthermore, Phospho-CTNNB1 (Y654) Antibody blocks anoikis of malignant kidney and intestinal epithelial cells, promoting their anchorage-independent growth by down-regulating DAPK2. It disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML. Additionally, Phospho-CTNNB1 (Y654) Antibody promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle. It is also involved in chondrocyte differentiation through interaction with SOX9, where SOX9-binding competes with the binding sites of TCF/LEF within CTNNB1, inhibiting Wnt signaling.
Gene References Into Functions
  1. CXC chemokine ligand 9 promotes the progression of diffuse large B-cell lymphoma in a beta-catenin-dependent manner. PMID: 30130730
  2. Research suggests that epigenetic regulation of CTNNB1 may serve as a novel approach to block colon cancer cell migration and invasion. PMID: 29923144
  3. Studies have shown that 2HF could inhibit EMT, cell migration, and invasion through the Wnt/bcatenin signaling pathway by suppressing GSK3b phosphorylation, betacatenin expression, and transactivation. PMID: 30226607
  4. Collectively, these studies indicate that the cellular transcription factor beta-catenin stimulates productive herpes simplex virus 1 infection, in part because VP16 enhances beta-catenin-dependent transcription. PMID: 30077727
  5. CTNNB1 mutations may be more associated with tumorigenesis (aldosterone-producing adenoma) rather than excessive aldosterone production. PMID: 28102204
  6. CTNNB1 mutations were identified in 60% of Basal cell adenoma but not in basal cell adenocarcinoma. None of the tested cases had PIK3CA mutations. CTNNB1 mutation trended to be more common in cases with a predominant tubular or tubulotrabecular pattern. PMID: 29224720
  7. Data reveal that post-translational modifications of beta-catenin in the ubiquitin-proteasome pathway yield a truncated beta-catenin molecule containing a serine 552-phosphorylated core region without N and C termini. This proteolytic processing of beta-catenin is required for binding with TCF4 and subsequent transcriptional activation. PMID: 29330435
  8. Results identify CTNNB1 as a Girdin-interacting protein. Girdin-depleted skin cancer cells displayed scattering and impaired E-cadherin-specific cell-cell adhesion. PMID: 30194792
  9. The dysregulation of TET2/E-cadherin/beta-catenin regulatory loop is a critical oncogenic event in HCC progression. PMID: 29331390
  10. High CTNNB1 expression is associated with bladder cancer progression. PMID: 30015971
  11. It has been found that miR-27a-3p modulated the Wnt/beta-catenin signaling pathway to promote epithelial-mesenchymal transition in oral squamous carcinoma stem cells by down-regulating SFRP1. PMID: 28425477
  12. The beta-catenin pathway is activated by CBX8 in hepatocellular carcinoma. PMID: 29066512
  13. Our data provide novel evidence for the biological and clinical significance of SPAG5 as a potential biomarker, demonstrating that SPAG5-b-catenin-SCARA5 might be a novel pathway involved in hepatocellular carcinoma progression. PMID: 30249289
  14. Results show that hypoxia enhanced nuclear accumulation and transcriptional activity of beta-catenin, promoting expression of EMT-related genes and eventually contributing to the metastatic process in lung cancer cells. PMID: 30396950
  15. This study demonstrates that FOXC1 induces cancer stem cells (CSCs)-like properties in non-small cell lung cancer (NSCLC) by promoting beta-catenin expression. The findings indicate that FOXC1 is a potential molecular target for anti-CSC-based therapies in NSCLC. PMID: 30189871
  16. High TBL1XR1 expression indicates poor disease-free survival of stage I-III colorectal cancer patients; beta-catenin signaling is critical for TBL1XR1-mediated colorectal cancer cells oncogenicity. PMID: 28295012
  17. Taken together, these results suggest that Wnt/beta-catenin signal pathway activation-dependent up-regulation of syncytin-1 contributes to the pro-inflammatory factor TNF-alpha-enhanced fusion between oral squamous cell carcinoma cells and endothelial cells. PMID: 28112190
  18. The disassociation of the beta-catenin/E-cadherin complex in the osteoblast membrane under stretch loading and the subsequent translocation of beta-catenin into the nucleus may be an intrinsic mechanical signal transduction mechanism. PMID: 29901167
  19. Aberrant CTNNB1 expression was seen in a substantial proportion of hepatocellular carcinoma (HCC) cases. CTNNB1-positive HCC was associated with normal AFP levels, unicentric tumors, well-differentiated histology, and an unfavorable outcome. PMID: 30082549
  20. Long noncoding RNA AFAP1-AS1 enhances cell proliferation and invasion in osteosarcoma through regulating miR-4695-5p/TCF4-beta-catenin signaling. PMID: 29901121
  21. High CTNNB1 expression is associated with the recurrence of Adamantinomatous Craniopharyngiomas. PMID: 29625497
  22. High CTNNB1 expression is associated with uterine fibroids. PMID: 29066531
  23. The nucleus and/or cytoplasm expression of beta-catenin was associated with tumor progression and correlated with overall survival of patients with ovarian cancer (OC). Beta-catenin may be a potential prognostic biomarker for patients with OC. [Review] PMID: 30103006
  24. In the two wild type (WT) cases, two novel alterations were detected: a complex deletion of APC and a pathogenic mutation of LAMTOR2. Focusing on WT DT subtype, deep sequencing of CTNNB1, APC and LAMTOR2 was conducted on a retrospective series of 11 WT DT using a targeted approach. PMID: 29901254
  25. DLX1 interacted with beta-catenin and enhanced the interaction between beta-catenin and TCF4 T-cell factor. PMID: 29317218
  26. Nuclear beta-catenin immunoreactivity with appropriate criteria may be helpful to distinguish basal cell adenocarcinoma (BCAC) from histologically similar tumors. However, a minor subset of adenoid cystic carcinoma (ACC) with nuclear beta-catenin expression require careful diagnosis. PMID: 29496310
  27. High CTNNB1 expression is associated with metastasis in cholangiocarcinoma. PMID: 30193944
  28. Beta-catenin directly interacts with the Cx43 carboxyl-terminal domain. PMID: 29882937
  29. This study showed that beta-catenin expression was most evident in the nucleus rather than in the cytoplasm. PMID: 29297710
  30. Nuclear beta-catenin accumulation in non-mitotic glioblastoma cells is due to a feed forward mechanism between DOCK4 and beta-catenin. PMID: 28925399
  31. Study found that HIF1alpha overexpression led to enhanced betacatenin nuclear translocation, while betacatenin silencing inhibited betacatenin nuclear translocation. The enhanced betacatenin nuclear translocation induced resulted in enhanced cell proliferation and cell invasion, altered cell cycle distribution, decreased apoptosis, and improved nonhomologous end joining repair under normal and irradiation conditions. PMID: 29658569
  32. Our results demonstrated that miR-188 inhibits glioma cell proliferation by targeting beta-catenin. PMID: 29268818
  33. Marked upregulation of beta-catenin and its downstream targets effectively enhanced hepatosphere formation, with an associated induction of CD133, OCT4 and Sox2 expression, and also caused a significant enhancement of HCC proliferation. PMID: 29792038
  34. The Wnt/beta-catenin signaling pathway may play a significant role in the pathogenesis of preeclampsia by regulating the invasion and proliferation of trophoblast. PMID: 29603045
  35. Associations between environmental variants together with single nucleotide polymorphisms (SNPs) of beta-catenin (ctnnb1) and lung cancer risk were analyzed using a logistic regression model. PMID: 29562493
  36. CTNNB1 is overexpressed and confers a poor prognosis in acute myeloid leukemia. PMID: 29496308
  37. High CTNNB1 expression is associated with cisplatin-resistance in non-small cell lung cancer. PMID: 30009824
  38. Beta-catenin immunopositivity is seen in the majority of cases of sinonasal sarcoma. PMID: 29566950
  39. For the first time, we demonstrated that rather than excluding lymphocytes infiltration as reported in melanoma, high levels of TILs were associated with beta-catenin overexpression in BC. PMID: 29286921
  40. Study shows that apigenin-induced lysosomal degradation of beta-catenin in Wnt/beta-catenin signaling. PMID: 28337019
  41. CRISPR-Cas9 technology was used to study the effect of knockout of catenin beta 1 (CTNNB1) on cell behavior and signal pathways in HEK293 cells. Results showed that knockout of CTNNB1 affected the Wnt/beta-catenin signaling pathway and suppressed adhesion and proliferation of HEK 293T cells. PMID: 29249062
  42. Our results also revealed that lncRNA SNHG20 knockdown inhibited Wnt/b catenin signaling activity by suppressing beta-catenin expression and reversing the downstream target gene expression. Taken together, lncRNA SNHG20 plays a pivotal role in ovarian cancer progression by regulating Wnt/b-catenin signaling. PMID: 29101241
  43. Wnt3A regulates the expression of 1,136 genes, of which 662 are upregulated and 474 are downregulated in CCD-18Co cells. A set of genes encoding inhibitors of the Wnt/beta-catenin pathway stand out among those induced by Wnt3A, suggesting that there is a feedback inhibitory mechanism. PMID: 29044515
  44. The aim of our study was to analyze the immunohistochemical expression of beta-catenin, E-cadherin, and Snail, depending on clinico-morphological aspects of laryngeal squamous cell carcinomas. Results revealed variable E-cadherin, beta-catenin, and Snail expression, depending on differentiation degree and tumor stage. PMID: 29250652
  45. In this study, we showed that the activation of the Wnt/beta-catenin pathway culminates in the upregulation of MGAT1 enzyme both at transcriptional and post-transcriptional levels. We also showed that overexpression of the beta-catenin gene (CTNNB1) increased the promoter activity of MGAT1. PMID: 29310626
  46. CTNNB1 mutation is associated with acquired resistance to KIT inhibitor in metastatic melanoma. PMID: 28421416
  47. Three CTNNB1 SNPs were suggested to have the potential to be novel biomarkers for risk prediction of cancer in the overall population or some specific subgroups. [Review] PMID: 28963373
  48. A CTNNB1 exon 3 mutation restricted to the areas exhibiting both positive glutamine synthetase (GS) and C-reactive protein (CRP) expression, whereas wild-type CTNNB1 was found in areas showing only CRP staining. These two cases illustrate focal beta-catenin activation that can occur within Inflammatory hepatocellular adenoma (IHCAs). PMID: 28618047
  49. Results show that the E-cadherin/beta-catenin complex is disrupted by ICAT, promoting epithelial-mesenchymal transition of cervical cancer cells. PMID: 29048651
  50. Toosendanin administration inhibited growth and liver metastasis of orthotopically implanted SGC7901 tumors in vivo through miR200amediated beta-catenin pathway. Our data suggest that Toosendanin may suppress oncogenic phenotypes of human GC cells partly via the miR200a/beta-catenin axis. Hence, Toosendanin may have promising chemotherapeutic activity for GC therapy. PMID: 29048657

Show More

Hide All

Database Links

HGNC: 2514

OMIM: 114500

KEGG: hsa:1499

STRING: 9606.ENSP00000344456

UniGene: Hs.476018

Involvement In Disease
Colorectal cancer (CRC); Pilomatrixoma (PTR); Medulloblastoma (MDB); Ovarian cancer (OC); Mesothelioma, malignant (MESOM); Mental retardation, autosomal dominant 19 (MRD19); Vitreoretinopathy, exudative 7 (EVR7)
Protein Families
Beta-catenin family
Subcellular Location
Cytoplasm. Nucleus. Cytoplasm, cytoskeleton. Cell junction, adherens junction. Cell junction. Cell membrane. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle pole. Cell junction, synapse. Cytoplasm, cytoskeleton, cilium basal body.
Tissue Specificity
Expressed in several hair follicle cell types: basal and peripheral matrix cells, and cells of the outer and inner root sheaths. Expressed in colon. Present in cortical neurons (at protein level). Expressed in breast cancer tissues (at protein level).

Q&A

Basic Research Questions

  • What is CTNNB1 and what role does Y654 phosphorylation play in its function?

    CTNNB1 (catenin beta-1) encodes β-catenin, a multifunctional protein that serves as a key downstream component of the canonical Wnt signaling pathway and participates in cell adhesion complexes . β-catenin functions through a dual mechanism: in the absence of Wnt signaling, it forms a complex with AXIN1, AXIN2, APC, CSNK1A1, and GSK3B that promotes its phosphorylation, ubiquitination, and subsequent proteasomal degradation; when Wnt is present, β-catenin accumulates and translocates to the nucleus to activate TCF/LEF target genes .

    Phosphorylation at tyrosine 654 (Y654) specifically affects β-catenin's ability to bind cadherins. Research demonstrates that Y654 phosphorylation:

    • Decreases the binding affinity between β-catenin and cadherins, particularly VE-cadherin

    • Promotes dissociation of adherens junctions (AJs)

    • Facilitates nuclear translocation of β-catenin

    • Modulates cytoskeletal organization and cell permeability

    Methodologically, investigating Y654 phosphorylation requires phospho-specific antibodies and can be validated using Y654F phospho-deficient mutants as negative controls .

  • What experimental techniques require Phospho-CTNNB1 (Y654) antibodies?

    Phospho-CTNNB1 (Y654) antibodies are validated for multiple experimental applications:

    ApplicationCommon UsesRecommended Dilutions
    Western Blot (WB)Detecting phosphorylated β-catenin in cell/tissue lysates1:500-1:1000
    Immunohistochemistry (IHC-P)Visualizing spatial distribution in paraffin-embedded tissues1:50-1:200
    Immunofluorescence (IF)High-resolution subcellular localization imaging1:100-1:500
    ELISAQuantitative measurement in biological samples1:1000-1:10000

    When designing experiments:

    • Include appropriate controls (phospho-deficient Y654F mutants)

    • Consider temporal dynamics of phosphorylation events

    • Use subcellular fractionation to assess compartment-specific phosphorylation

    • Combine with other readouts of β-catenin activity (e.g., TCF/LEF reporter assays)

  • How does Y654 phosphorylation affect β-catenin localization and interactions with binding partners?

    Y654 phosphorylation significantly alters β-catenin's molecular interactions and subcellular distribution:

    • Reduces binding affinity to cadherins, leading to dissociation from adherens junctions

    • Promotes nuclear accumulation, with studies showing that nuclear/cytoplasmic ratios increase following stimuli that induce Y654 phosphorylation

    • Affects the composition of β-catenin-containing complexes in both cytoplasm and nucleus

    • Shifts β-catenin from a membrane-bound to cytoplasmic/nuclear pool

    Research demonstrates that β-catenin Y654 dephosphorylation attenuates HMGB1-mediated dissociation of VE-cadherin/β-catenin complexes, reducing endothelial hyperpermeability in experimental models . This suggests a mechanistic role for Y654 phosphorylation in regulating vascular barrier function.

    When studying these dynamics, quantitative live-cell imaging approaches have revealed that the nuclear accumulation of β-catenin is favored over cytoplasmic increases following stimulation, with statistically significant nuclear increases detected approximately 30 minutes after treatment compared to 45 minutes for cytoplasmic increases .

Advanced Research Questions

  • How do different signaling pathways converge on Y654 phosphorylation of β-catenin?

    Multiple signaling cascades can trigger Y654 phosphorylation through distinct mechanisms:

    • Inflammatory mediators: HMGB1 (High Mobility Group Box-1) activates Y654 phosphorylation leading to endothelial barrier dysfunction in sepsis models

    • Growth factor signaling: Several receptor tyrosine kinases can phosphorylate Y654

    • Cellular stress responses: Oxidative stress and hypoxia have been implicated in altered Y654 phosphorylation states

    Methodological approaches to investigate these pathways include:

    1. Specific kinase inhibitors to identify responsible enzymes

    2. Time-course experiments following stimulation

    3. Genetic approaches using kinase knockdown/knockout models

    4. Phospho-proteomics to identify associated modifications

    5. In vivo models with pathway-specific activators/inhibitors

    When specifically studying HMGB1-induced phosphorylation of β-catenin Y654 in endothelial cells, research has demonstrated that this modification triggers adherens junction disruption and cytoskeletal rearrangement, contributing to vascular leakage in models of acute lung injury .

  • What is the relationship between Y654 phosphorylation and disease states?

    Y654 phosphorylation has been implicated in several pathological conditions:

    • Acute lung injury/sepsis: Phospho-deficiencies at both β-catenin Y654 and Y142 ameliorated pulmonary vascular dysfunction in cecal ligation and puncture models in mice

    • Cancer progression: Aberrant phosphorylation may contribute to dysregulated Wnt/β-catenin signaling

    • Neurodevelopmental disorders: While CTNNB1 mutations are strongly associated with intellectual disability and autism spectrum disorders , the specific role of Y654 phosphorylation in these contexts requires further investigation

    Experimental approaches to study disease relevance include:

    1. Animal models expressing phospho-deficient (Y654F) mutants

    2. Patient-derived samples analyzed with phospho-specific antibodies

    3. In vitro disease models using relevant cell types and disease-specific stimuli

    4. Correlation of phosphorylation status with clinical outcomes

    Research has shown that phospho-deficiencies at Y654 significantly reduced pulmonary vascular permeability in experimental sepsis, suggesting therapeutic potential in targeting this modification .

  • How does Y654 phosphorylation interact with other post-translational modifications of β-catenin?

    β-catenin undergoes complex patterns of post-translational modifications that influence its stability, localization, and function:

    Modification TypeSitesFunctional ImpactInteraction with Y654
    PhosphorylationN-terminal Ser/Thr (S33/S37/T41/S45)Targets for degradationY654 phosphorylation may affect accessibility
    PhosphorylationY142Disrupts α-catenin bindingOften co-regulated with Y654
    UbiquitinationMultiple lysinesMediates proteasomal degradationAffected by phosphorylation status
    AcetylationMultiple lysinesInfluences nuclear functionsMay compete with phosphorylation-dependent interactions

    Research shows that Y654 and Y142 phosphorylation sites have distinct but complementary effects: Y142 dephosphorylation prevents HMGB1-induced uncoupling of β-catenin and α-catenin, while Y654 dephosphorylation attenuates dissociation of VE-cadherin/β-catenin complexes .

    Methodological approaches to study these interactions include:

    • Mass spectrometry to identify multiple modifications simultaneously

    • Sequential immunoprecipitation with different modification-specific antibodies

    • CRISPR-Cas9 editing to create combinations of phospho-deficient mutations

    • Computational modeling to predict modification crosstalk

  • What are the methodological considerations for differentiating between total and phosphorylated β-catenin in experimental settings?

    Accurately distinguishing phosphorylated from total β-catenin requires careful experimental design:

    • Antibody validation: Confirm specificity using phospho-deficient mutants (Y654F) and phosphatase treatment

    • Controls: Include both positive controls (treatments known to induce phosphorylation) and negative controls

    • Normalization: Quantify phospho-signal relative to total β-catenin levels

    • Subcellular fractionation: Separate cellular compartments before analysis to detect redistribution

    • Kinetics: Consider temporal dynamics with time-course experiments

    Technical recommendations:

    1. Use peptide competition assays with phosphorylated and non-phosphorylated peptides

    2. Consider the immunogen sequence when selecting antibodies (synthetic peptide derived from human Catenin-beta around Y654)

    3. Use multiple detection methods (WB, IF, IHC) to confirm findings

    4. Correlate phosphorylation with functional readouts like TCF/LEF reporter activity

    5. For accurate quantification, use fluorescence correlation spectroscopy (FCS) or number and brightness (N&B) analysis

  • How can phospho-deficient and phospho-mimetic β-catenin mutants be used to study Y654 phosphorylation functions?

    Mutational approaches provide powerful tools for dissecting phosphorylation functions:

    • Y654F (phospho-deficient): Prevents phosphorylation by replacing tyrosine with non-phosphorylatable phenylalanine

    • Y654E (phospho-mimetic): Introduces negative charge to simulate constitutive phosphorylation

    Research applications include:

    1. In vitro studies:

      • Express mutants in β-catenin knockout backgrounds

      • Compare protein-protein interactions using co-immunoprecipitation

      • Assess subcellular localization via immunofluorescence

      • Measure transcriptional activity using reporter assays

    2. In vivo models:

      • Generate knock-in mice expressing Y654F to study physiological relevance

      • Compare phenotypes with disease models

      • Assess tissue-specific effects

    Studies employing Y654F mutants have demonstrated that phospho-deficiency at this site ameliorates pulmonary vascular dysfunction in sepsis models, confirming the functional significance of this modification in pathological contexts .

  • What biophysical techniques can be applied to study Y654 phosphorylation effects on β-catenin dynamics?

    Advanced biophysical methods offer insights into β-catenin dynamics:

    • Fluorescence Recovery After Photobleaching (FRAP): Measures mobility and exchange rates between compartments

    • Fluorescence Correlation Spectroscopy (FCS): Detects changes in diffusion speeds of β-catenin complexes

    • Number and Brightness (N&B) analysis: Quantifies molecular brightness and oligomerization state

    • Single-molecule tracking: Follows individual β-catenin molecules in real-time

    • Förster Resonance Energy Transfer (FRET): Detects conformational changes upon phosphorylation

    Research using these approaches has revealed:

    1. β-catenin exists in multiple diffusion states in both cytoplasm and nucleus

    2. A two-component model best fits experimental data, with one component representing monomeric β-catenin (14.9 μm²/s) and another representing larger complexes

    3. Phosphorylation status affects the size and composition of these complexes

    4. The nuclear/cytoplasmic ratio of β-catenin (measured as 0.652 in unstimulated cells) increases upon pathway activation

    These quantitative approaches demonstrate that both subcellular retention and active nuclear import/export mechanisms contribute to β-catenin localization following Y654 phosphorylation events .

  • How does Y654 phosphorylation influence β-catenin's role in different cellular contexts?

    β-catenin Y654 phosphorylation exhibits distinct effects across various cellular systems:

    Cell/Tissue TypeY654 Phosphorylation EffectsExperimental Approaches
    Endothelial cellsDisrupts VE-cadherin binding, increases permeabilityTransendothelial resistance, dextran leakage assays
    Epithelial cellsDecreases E-cadherin binding, affects epithelial integrityCalcium switch assays, barrier function tests
    NeuronsMay affect synaptic plasticity and developmentElectrophysiology, neurite outgrowth assays
    Cancer cellsPotentially increases nuclear signaling, affecting proliferationReporter assays, proliferation/migration assays

    Context-specific considerations:

    1. Different kinases may target Y654 in different tissues

    2. The balance between membrane, cytoplasmic, and nuclear pools varies by cell type

    3. The composition of adherens junctions differs across tissues

    4. Interaction with tissue-specific transcription factors may be affected

    Methodologically, comparative studies across multiple cell types using identical stimuli and readouts can help identify context-specific mechanisms. Primary cells from phospho-deficient mouse models provide particularly valuable insights into tissue-specific functions .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.